University of California

Kenneth Kosik

Paul K Hansma

Barney Drake

Daniel C Bridges

Connor J Randall

Israel Hernandez

Luke S K Theogarajan

Kenneth R Tovar

The invention is directed to the treatment of tauopathic neurodegenerative conditions and the underlying processes thereof. Based on the discovery that Rhes acts as a negative regulator of normal tau clearance, the compositions and methods of the invention may be applied to inhibit Rhes and reduce pathogenic tau aggregation. Rhes may be disrupted by disrupting RAS2D gene expression or reducing the abundance of Rhes protein in neurons. Additionally, post-translational modifications of Rhes may be targeted, including the disruption of Rhes farnesylation by the administration of farnesyltransferase inhibitors.

Treatment of neurodegenerative conditions by disruption of Rhes

A Neural Circuit Probe (NCP) combines a multi-electrode array (MEA) with an automated local probe, wherein the probe is positioned to interact with one or more cells, such as neurons of a neural circuit, grown on or about one or more electrodes of the multi-electrode array. The probe may interact with the cells by electrically recording signals from the multi-electrode array that are assigned to a specific one of the cells. The probe may interact with the cells by locally delivering chemicals to the cells, which transiently and reversibly modulate the electrical behavior of the cells. The probe may interact with the cells by harvesting the cells using a pipette, so that the harvested cells can be sequenced.

Neural circuit probe

Growing community of inventors

Santa Barbara, CA, United States of America

Kenneth Kosik